Гистохром is commonly used in therapeutic domains focused on supporting the maintenance of vision and managing acute symptoms within the eye. It contributes to easing the overall symptom load and helps maintain a sense of stability for the patient.

The medication is relevant for symptoms associated with acute or episodic changes, specifically impaired vision and clouding caused by internal bleeding. This use is targeted at conditions such as intraocular hemorrhages and certain vascular membrane disorders. The drug helps with the process of hemoresorption, assisting the body with the clearing of blood residues, which supports the easing of symptoms related to visual obstruction.

In chronic settings, the application is relevant for conditions marked by a progressive decline in retinal or optic nerve function. The medication provides supportive therapeutic benefit to eye tissues. The use of compounds with properties relevant to this domain may be part of symptomatic management in such chronic degenerative diseases. This action supports functional stability and the maintenance of vision over time. The medicine is also applied in settings of heightened physiological stress, such as following surgical procedures or injury, to provide supportive benefit to the tissues.

“Supportive care assists with managing symptoms that interfere with recovery and supports general well-being during symptomatic phases.”

---

Quick Fact: Relief for Ocular Symptoms

Гистохром is applied across several therapeutic domains: managing acute symptoms related to intraocular bleeding, offering protective support in chronic retinal degeneration, and assisting with tissue resilience in post-traumatic scenarios.

---

Regulatory References

1. National Institutes of Health (NIH) study on Age-Related Macular Degeneration (AMD)

Eligibility Profile

The eligibility for the use of Гистохром (Pentahydroxyethylnaphtoquinone) is strictly governed by population-based restrictions defined in official regulatory documents. Use is formally permitted only in Adults.

---

Official Regulatory Status

Population Group	Eligibility Status
Adults (18+ years)	Allowed
Children & Adolescents (<18 years)	Contraindicated
Pregnant Women	Contraindicated
Lactating Women	Contraindicated
Hypersensitivity	Contraindicated

---

The medicine is contraindicated and must not be used by several specific populations. This prohibition includes all children and adolescents under 18 years of age, as official regulatory data explicitly state that the product’s safety and efficacy are not established in this pediatric group. The medicine is also formally contraindicated for pregnant women and lactating women; safety of use in these physiological states has similarly not been established in regulatory data.

Use is also contraindicated for any individual with a known hypersensitivity to the active component or to any excipient present in the formulation. The official eligibility profile thus defines who can and cannot use the medicine primarily through these clear, label-based exclusions.

Interaction Map: Interactions with other medicines and products — official regulatory information for Гистохром

Interaction scope

Medicinal product categories with documented interactions: Not explicitly detailed in official regulatory documents found in publicly accessible international sources. Specific interacting medicines (if explicitly listed): None explicitly listed in official regulatory documents found. Mechanistic basis of interactions (only if stated in label): No specific Pharmacokinetic (PK) mechanisms, such as Cytochrome P450 enzyme or transporter modulation, are explicitly described in official documents. Timing-based interaction rules (if applicable): No mandatory administration timing or separation requirements are explicitly documented. Population-specific interaction notes (if applicable): No specific interaction considerations related to renal or hepatic impairment or other special populations are explicitly documented. Interaction-related restrictions: No specific do-not-combine restrictions or required monitoring alerts are explicitly documented.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Not formally classified in the official documents found. Regulatory basis (EMA / FDA / etc.): Not explicitly detailed in the interaction section of official documents found. Interaction-context constraints (as defined in official documents): No constraints regarding food, alcohol, or herbal products are explicitly documented.

Resulting interaction structure

• No specific drug-drug interactions resulting in an alteration of systemic exposure or pharmacologic effect are explicitly documented.
• No Pharmacodynamic interactions leading to additive toxic effects are explicitly stated in the official texts found.
• No non-medicinal product interactions, such as those involving food or herbal supplements, are explicitly documented in the official interaction section.

Connection to the overall interaction profile (4 sentences): The available regulatory documentation does not explicitly define a formal structure or list of interacting agents for Гистохром. The product's official interaction profile, based on verifiable regulatory texts, currently contains no specified constraints or requirements for co-administration with other medicinal products. Consequently, there are no documented instructions regarding the management of altered plasma levels or the avoidance of specific pharmacological risks due to concomitant use. The absence of specific interaction-related text indicates that the product's regulatory labeling does not mandate specific drug-drug or drug-food combination requirements.

The action of Гистохром (Pentahydroxyethylnaphtoquinone) is entirely focused on influencing fundamental biochemical processes that underpin cellular stress and damage in ocular tissues.

---

Direct Free Radical Intervention and Iron Chelation

This domain outlines the drug's initial molecular activity, where it functions as a bioantioxidant. The drug's structure allows it to act as a direct scavenger of damaging Reactive Oxygen Species (ROS). Crucially, it employs chelation to bind and inactivate Iron Cations, thereby stopping the iron-catalyzed chain reactions (Fenton chemistry) that generate highly destructive radicals. This dual action rapidly lowers the local oxidative load, which contributes to the stabilization of the cellular environment.

---

Cellular Membrane Protection and Ferroptosis Blockade

This domain focuses on the cascade effect of reduced oxidative stress. By inhibiting the destructive Lipid Peroxidation (LPO) cascade, the drug prevents the breakdown of cellular and mitochondrial membranes. This action maintains cell viability, preventing an iron-dependent form of cell death known as ferroptosis, supporting the sustained function of ocular structures.

---

Angioprotection and Hemo-Resolution Support

This domain covers the drug's effect on microcirculation and tissue clearance. The preservation of endothelial cell integrity—a consequence of reduced oxidative damage—stabilizes the microvasculature, which limits leakage and the development of edema. Furthermore, the drug's properties support the physical dissolution and clearance of blood components, influencing the process of hemoresorption (natural clearing of blood residues).

Administration Guidelines for Гистохром

This section outlines the procedural steps for administering Гистохром, excluding all information related to therapeutic effects, safety, or clinical rationale.

Administration Scope	Detail
Route of Administration	Localized injection: Subconjunctival or Parabulbar.
Dosing Schedule	0.5 ml of 0.02% solution per administration.
Frequency Pattern	Daily, once per day.
Course Duration	A full course consists of 7 to 10 total injections.

---

Procedural Structure

The administration is a defined course delivered via injection. The preparation involves obtaining the pre-constituted 0.02% solution. No additional dilution or reconstitution steps are detailed.

Step Sequence:

1. Preparation: A dose of 0.5 ml of 0.02% solution is drawn up for injection.
2. Administration: The solution is administered via the subconjunctival or parabulbar route.
3. Frequency: The injection is repeated daily.
4. Completion: The treatment involves completing a course that totals 7 to 10 separate injections.

---

Instruction Classifications

• Administration Method Type: Localized Ocular Injection.
• Jurisdiction context: Russian Federation.
• Use-Context Constraints: The medication is administered as a fixed-duration course of injections. Missed dose instructions and specific timing (e.g., in relation to food or time of day) are not explicitly documented as part of the procedural requirements.

Research evidence / Overview of studies for Гистохром

1. Evidence for Acute Ocular Hemorrhage

Research on Гистохром was studied for its use in managing acute intraocular hemorrhage, which involves internal bleeding inside the eye. The available evidence for this indication is largely classified as moderate in certainty.

These studies primarily examined outcomes related to physical discomfort and outcomes describing episodic or acute changes within the eye, using controlled clinical trials where research subjects were compared to others. Research explored outcomes related to the rate of hemoresorption (the clearance of blood residues), alongside functional measures. The research design focused on episodes of bleeding that occurred within a short time frame (acute onset). The evidence is limited in describing the medicine’s effect on hemorrhages that are not recent, and the follow-up durations were limited.

2. Evidence for Degenerative Processes of the Retina and Optic Nerve

The research on Гистохром was evaluated in the context of conditions marked by functional limitations and degenerative processes, particularly those affecting the retina and optic nerve. This evidence base, which is generally considered low in certainty, consists mainly of clinical studies and case series. These studies explored the drug's role in providing supportive therapeutic benefit to ocular tissues.

Instead of measuring long-term vision, the studies monitored surrogate biological markers, specifically changes in electrophysiological parameters. The research structure highlights the reliance on these surrogate endpoints rather than outcomes linked to long-term functional vision, such as sustained visual acuity. There is a lack of long-term data to characterize the durability of any supportive or protective effects over extended periods.

5. What is Still Uncertain About the Research Base

Research on Гистохром highlights what is known — and what is still uncertain. The existing evidence quality varies across studies, and a significant area of uncertainty involves the reliance on indirect measurements. Sample sizes were modest in some key comparative trials, and there is a general lack of comparative evidence against other therapies in some contexts. Finally, long-term effects are not fully established, and current evidence does not clarify the durability of any observed patterns.

Key Studies & References NIH study confirms benefit of supplements in slowing age-related macular degeneration (Used for Contextual Framing of Supportive Care)

Common questions about Гистохром (FAQ)

Q: Does Гистохром treat all eye conditions, or just specific ones?

Studies and official information indicate that the medicine has been examined in the context of specific conditions, notably acute intraocular hemorrhage and certain degenerative processes of the retina and optic nerve. Its regulatory status means its formal application is defined by specific, approved therapeutic indications, not a broad use for all eye conditions.

Q: How quickly should I expect to see any difference after starting Гистохром?

Official regulatory documentation does not provide a general expectation for the onset of the medicine’s supportive effects. Research evidence relating to acute hemorrhage has primarily focused on data collected within a short time frame following application.

Q: What is the difference between Гистохром and similar eye drops I see advertised?

Гистохром is classified as a unique Bioantioxidant and Retinoprotector. Its active ingredient is a synthetic quinone derivative based on a natural prototype. A key distinguishing factor is that it is formulated for use as both an ophthalmic solution and an injectable solution for localized delivery.

Q: Can Гистохром be used for general eye wellness or preventative care?

The medicine is officially classified as a Retinoprotector, indicating its function in providing protection against oxidative damage to the retina. Its formal use is restricted to conditions covered by its regulatory-approved indications, not general wellness.

Q: What happens if I miss a scheduled application of Гистохром?

Official administration guidelines, based on regulatory sources, state that missed dose instructions are not explicitly documented as part of the mandatory procedural requirements for the course of injections.

Q: Is it safe to use Гистохром if I have glaucoma?

The official regulatory documents do not list specific constraints regarding co-morbidities like glaucoma or other chronic systemic conditions. Restrictions on use are explicitly defined by contraindications related to patient population (age, pregnancy) and hypersensitivity to the drug components.

Q: Can Гистохром be used by people with allergies to common medications?

The medicine is formally contraindicated only for individuals with a known hypersensitivity to the active component or to any excipient contained in the formulation. Official documentation does not provide restrictions concerning general allergies to other medication classes.

Q: What are the most common misunderstandings people have about Гистохром?

Official documents can help clarify common points of misunderstanding. These often relate to the safety profile, where the statement that "no adverse effects were registered" means the frequency is "Not Known" rather than zero. Another point of clarification is the drug’s nature as a synthetic derivative of a natural marine quinone.

Q: Has Гистохром been approved by international health organizations?

The primary regulatory basis cited in official documentation is the Russian Federation. The provided regulatory texts do not explicitly mention approval status by major international bodies, such as the FDA (United States), EMA (Europe), or Health Canada.

Q: Why might a doctor switch me from another drug to Гистохром?

The drug possesses specific molecular properties, including the ability to act as a direct free radical scavenger and employing specific iron chelation—a process known as Ferroptosis Blockade. These unique mechanistic actions define the drug's role in tissue support, which may inform its selection by a medical professional.

Q: Does the efficacy of Гистохром vary based on the stage of the eye condition?

Research evidence indicates that studies were primarily focused on conditions of acute onset. Documentation notes that research is limited in describing the effect of the medicine on hemorrhages that are not recent or chronic.

Q: What is the purpose of the 'How it works' description for Гистохром?

The description serves to provide factual, high-level explanations of the drug’s core actions, without giving clinical advice. It clarifies its classification and function, such as its role as a Bioantioxidant and Retinoprotector influencing cellular stress and damage in ocular tissues.

Q: Where can I find the official regulatory information about Гистохром?

The primary regulatory documents cited originate from the Russian Federation. Supporting documentation and study information are also accessible in databases such as the NIH Clinical Trial Database.

Q: What is the difference between the listed 'main uses' and 'benefits' of Гистохром?

Official documentation describes the drug’s purpose as offering protection against oxidative damage (a function or potential benefit). The main uses refer to the specific, formal indications—the diseases or conditions approved for treatment by regulatory bodies.

Q: Is it true that Гистохром is used for vision improvement?

Research on the medicine focuses on providing supportive therapeutic benefit to tissues and monitoring changes in surrogate biological markers. The evidence base does not primarily measure outcomes related to long-term functional vision, such as sustained visual acuity.

Q: What is the shelf life of Гистохром once the package is opened?

Official documents clearly specify the overall unopened shelf life is 2 or 3 years, depending on the formulation. However, the regulatory documentation does not explicitly specify the stability or duration of use once the package or vial is opened for administration.

How to Store and Dispose of Гистохром (Histochrome)

Official regulatory documentation provides explicit instructions for the storage, handling, and disposal of Гистохром. Adherence to these requirements is mandatory to ensure drug stability and safety.

Storage Category	Official Requirements
Temperature Range	Store at a temperature from 8,^circmathrmC to 25,^circmathrmC.
Light Protection	Store in a protected from light place.
Child Safety	Store in a place out of reach of children.
Stability Period	Shelf life is 2 or 3 years (depending on product concentration).
Disposal Rule	Do not use the medicine after the expiry date indicated on the package.

Strictly follow the stated temperature range and ensure the product remains protected from light. The medicine must not be used past the expiration date listed on the packaging.